Inferra AIResearch Tools

Inferra AI / Company / ABT

Abbott Laboratories

ABT · Health Care

Last earnings Oct 21, 2026

Important announcements

Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded companyOct 21, 2026

Key results

Third-quarter GAAP EPSquarter

$0.94

Third-quarter GAAP diluted EPS of $0.94 adjusted

SEC original ↗Abbott Laboratories — Earnings release (8-K exhibit)EX-99Oct 15, 2025

Operating marginquarter

23.0 percent

operating margin of 23.0 percent, which reflects a 40 basis point increase ABBOTT PARK, Ill.

SEC original ↗Abbott Laboratories — Earnings release (8-K exhibit)EX-99Oct 15, 2025

Adjusted EPSquarter

$1.30

Third-quarter GAAP diluted EPS of $0.94 and adjusted diluted EPS of $1.30, which excludes specified items.

SEC original ↗Abbott Laboratories — Earnings release (8-K exhibit)EX-99Oct 15, 2025

Gross marginquarter

$ 470

3Q24 As Reported (GAAP) Specified Items As Adjusted Intangible Amortization $ 470 $ (470) $ Gross Margin 5,467 516 5,983 R D 713 (19) 694 SG A 2,895 (5) 2,890 Other (income) expense, net (121) (12) (133) Earnings before taxes 1,940 552 2,492 Taxes on Earnings 294 79 373 Net Earnings 1,646 473 2,119 Diluted Earnings per Share $ 0.94 $ 0.27 $ 1.21 Specified items reflect intangible amortization expense of $470 million and other net expenses of $82 million associated with charges related to intangible impairment, acquisitions, a divestiture and other net expenses.

SEC original ↗Abbott Laboratories — Earnings release (8-K exhibit)EX-99Oct 15, 2025

9M24 As Reported (GAAP) Specified Items As Adjusted Intangible Amortization $ 1,413 $ (1,413) $ Gross Margin 15,799 1,540 17,339 R D 2,095 (81) 2,014 SG A 8,790 (96) 8,694 Other (income) expense, net (222) (183) (405) Earnings before taxes 4,983 1,900 6,883 Taxes on Earnings 810 222 1,032 Net Earnings 4,173 1,678 5,851 Diluted Earnings per Share $ 2.38 $ 0.95 $ 3.33 Specified items reflect intangible amortization expense of $1.413 billion and other net expenses of $487 million associated with restructuring actions, acquisitions, a divestiture and other net expenses.

SEC original ↗Abbott Laboratories — Earnings release (8-K exhibit)EX-99Oct 15, 2025

AI analysis

Q3 2025 · reported Oct 15, 2025

Based on: Earnings release + parent 8-K — transcript not held

Third-quarter GAAP EPS · Q3 2025
$0.94
EX-99 · Oct 15, 2025
Operating margin · Q3 2025
23.0 percent
EX-99 · Oct 15, 2025
Adjusted EPS · Q3 2025
$1.30
EX-99 · Oct 15, 2025
Gross margin · Q3 2025
$470M
EX-99 · Oct 15, 2025

Headline figures

MetricQ3 2025Prior qtrYear ago
Third-quarter GAAP EPS$0.94——
Operating margin23.0 percent——
Adjusted EPS$1.30——
Gross margin$470M——

EX-99 · Oct 15, 2025

Guidance · company-stated

Direction: Raised

Revenue

“htm EX-99.1 Document Exhibit 99.1 News Release Abbott Reports Third-Quarter 2025 Results and Reaffirms Full-Year Guidance Third-quarter reported sales growth of 6.9 percent organic sales growth of 5.5 percent or 7.5 percent excluding COVID-19 testing-related sales 1 Third-quarter GAAP diluted EPS of $0.94 adjusted diluted EPS of $1.30 Reported operating margin of 18.1 percent of sales adjusted operating margin of 23.0 percent, which reflects a 40 basis point increase ABBOTT PARK, Ill.”

Revenue

“Abbott reaffirms previously provided full-year 2025 organic sales growth guidance.”

EPS

“Abbott reaffirms the midpoint of previously provided full-year 2025 adjusted diluted EPS guidance range and narrows the range to $5.12 to $5.18, reflecting double-digit growth at the midpoint.”

Revenue

“14.4 16.7 12.2 12.4 5.6 14.1 0.3 23.2 International 10.7 3.2 10.5 14.6 4.0 11.2 20.8 14.9 Page 6 of 20 ABBOTT'S FINANCIAL GUIDANCE Abbott reaffirms previously provided full-year 2025 organic sales growth guidance of 7.5% to 8.0%, excluding COVID-19 testing-related sales, or 6.0% to 7.0%, when including COVID-19 testing-related sales.”

EPS

“Abbott also reaffirms the midpoint of the previously provided full-year 2025 adjusted diluted EPS guidance range and narrows the range to $5.12 to $5.18, which reflects double-digit growth at the midpoint.”

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

Margin

Operating margin23.0 percent
Gross margin$ 470

Capital allocation

Dividend$0.59

ABBOTT DECLARES 407 th CONSECUTIVE QUARTERLY DIVIDEND On Sept.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

In July, Abbott announced it received regulatory approval in Japan for TriClip , a first of-its-kind, minimally invasive treatment option for patients with tricuspid regurgitation, or a leaky tricuspid heart valve

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

Direction: Raised

Revenue: “htm EX-99.1 Document Exhibit 99.1 News Release Abbott Reports Third-Quarter 2025 Results and Reaffirms Full-Year Guidance Third-quarter reported sales growth of 6.9 percent organic sales growth of 5.5 percent or 7.5 percent excluding COVID-19 testing-related sales 1 Third-quarter GAAP diluted EPS of $0.94 adjusted diluted EPS of $1.30 Reported operating margin of 18.1 percent of sales adjusted operating margin of 23.0 percent, which reflects a 40 basis point increase ABBOTT PARK, Ill.”

Revenue: “Abbott reaffirms previously provided full-year 2025 organic sales growth guidance.”

EPS: “Abbott reaffirms the midpoint of previously provided full-year 2025 adjusted diluted EPS guidance range and narrows the range to $5.12 to $5.18, reflecting double-digit growth at the midpoint.”

Revenue: “14.4 16.7 12.2 12.4 5.6 14.1 0.3 23.2 International 10.7 3.2 10.5 14.6 4.0 11.2 20.8 14.9 Page 6 of 20 ABBOTT'S FINANCIAL GUIDANCE Abbott reaffirms previously provided full-year 2025 organic sales growth guidance of 7.5% to 8.0%, excluding COVID-19 testing-related sales, or 6.0% to 7.0%, when including COVID-19 testing-related sales.”

EPS: “Abbott also reaffirms the midpoint of the previously provided full-year 2025 adjusted diluted EPS guidance range and narrows the range to $5.12 to $5.18, which reflects double-digit growth at the midpoint.”

Revenue — Raised (“increase”)
“htm EX-99.1 Document Exhibit 99.1 News Release Abbott Reports Third-Quarter 2025 Results and Reaffirms Full-Year Guidance Third-quarter reported sales growth of 6.9 percent organic sales growth of 5.5 percent or 7.5 percent excluding COVID-19 testing-related sales 1 Third-quarter GAAP diluted EPS of $0.94 adjusted diluted EPS of $1.30 Reported operating margin of 18.1 percent of sales adjusted operating margin of 23.0 percent, which reflects a 40 basis point increase ABBOTT PARK, Ill.”

Revenue — Reiterated (“reaffirms”)
“Abbott reaffirms previously provided full-year 2025 organic sales growth guidance.”

EPS — Reiterated (“reaffirms”)
“Abbott reaffirms the midpoint of previously provided full-year 2025 adjusted diluted EPS guidance range and narrows the range to $5.12 to $5.18, reflecting double-digit growth at the midpoint.”

Revenue — Reiterated (“reaffirms”)
“14.4 16.7 12.2 12.4 5.6 14.1 0.3 23.2 International 10.7 3.2 10.5 14.6 4.0 11.2 20.8 14.9 Page 6 of 20 ABBOTT'S FINANCIAL GUIDANCE Abbott reaffirms previously provided full-year 2025 organic sales growth guidance of 7.5% to 8.0%, excluding COVID-19 testing-related sales, or 6.0% to 7.0%, when including COVID-19 testing-related sales.”

EPS — Reiterated (“reaffirms”)
“Abbott also reaffirms the midpoint of the previously provided full-year 2025 adjusted diluted EPS guidance range and narrows the range to $5.12 to $5.18, which reflects double-digit growth at the midpoint.”

Classified from the release's primary full-year outlook statement.

Capital allocation

ABBOTT DECLARES 407 th CONSECUTIVE QUARTERLY DIVIDEND On Sept.

SEC original ↗Abbott Laboratories — Earnings release (8-K exhibit)EX-99Oct 15, 2025

19, 2025, the board of directors of Abbott declared the company's quarterly dividend of $0.59 per share.

SEC original ↗Abbott Laboratories — Earnings release (8-K exhibit)EX-99Oct 15, 2025

Abbott's cash dividend is payable Nov.

SEC original ↗Abbott Laboratories — Earnings release (8-K exhibit)EX-99Oct 15, 2025

Abbott has increased its dividend payout for 53 consecutive years and is a member of the S P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

SEC original ↗Abbott Laboratories — Earnings release (8-K exhibit)EX-99Oct 15, 2025

Strategy & priorities

Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP.

SEC original ↗Abbott Laboratories — Earnings release (8-K exhibit)EX-99Oct 15, 2025

2) 2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $634 million, or $0.36 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, and other net expenses.

SEC original ↗Abbott Laboratories — Earnings release (8-K exhibit)EX-99Oct 15, 2025

2) 2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.662 billion, or $0.95 per share, for intangible amortization, charges related to investment impairments, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses.

SEC original ↗Abbott Laboratories — Earnings release (8-K exhibit)EX-99Oct 15, 2025

2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.678 billion, or $0.95 per share, for intangible amortization, charges related to intangible impairment, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and a divestiture, and other net expenses.

SEC original ↗Abbott Laboratories — Earnings release (8-K exhibit)EX-99Oct 15, 2025

b) Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.

SEC original ↗Abbott Laboratories — Earnings release (8-K exhibit)EX-99Oct 15, 2025

Risks & headwinds

Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.

SEC original ↗Abbott Laboratories — Earnings release (8-K exhibit)EX-99Oct 15, 2025

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care
Documents

Filings

60 documents

Earnings releases

26 documents

Presentations

none published

Checked — this company publishes no earnings presentation. Checked 2026-10-20 (browser-verified): Abbott publishes no earnings deck — its quarters offer a press release and earnings infographic only.

Transcripts

0 documents

No transcripts for Abbott Laboratories are held in this edition of the library.

See also the earnings calendar for every tracked company’s next earnings date.